Xeme Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.xemebiopharma.com
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Follicular Lymphoma
- Interventions
- Biological: Oncoquest-L vaccine
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- XEME Biopharma Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02194751
- Locations
- 🇺🇸
Southeastern Regional Medical Center at CTCA, Newnan, Georgia, United States
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Phase 1
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Biological: Oncoquest-CLL vaccine
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- XEME Biopharma Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01976520
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath